Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077251 | 1.00 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2077738 | 0.80 | ATM (0.35) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2513974 | 0.80 | ATM (0.35) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2077742 | 0.80 | ATM (0.35) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9159289 | 0.68 | CHRNB2 (0.31) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9159278 | 0.68 | CHRNB2 (0.31) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5198167 | 0.68 | BRD4 (0.34) | — | |
| SCHEMBL10456620 | 0.67 | MMP2 (0.30) | — | |
| SCHEMBL5872252 | 0.66 | CYP1A2 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5872329 | 0.66 | CYP1A2 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2886530-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014027696-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | 中外製薬株式会社 (JP) | 2014-02-20 | — | — | WO | disclosed |
| US-8030496-B2 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKI KABUSHIKI KAISHA (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7897783-B2 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100152456-A1 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-06-17 | — | — | US | disclosed |
| US-20100152457-A1 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-06-17 | — | — | US | disclosed |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2008-11-27 | — | — | US | disclosed |
| EP-1857456-A1 | PROCESS FOR PRODUCING COMPOUND WITH ANTI-HCV POTENCY AND INTERMEDIATE FOR USE THEREIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | ZC3HAV1, SLC10A1, CYP51A1 | ALDH1A1 558/4885CYP1A2 134/4885CYP3A4 127/4885 |
| US-20100152457-A1 | Intermediate compound for synthesis of viridiofungin a derivative | ZC3HAV1, ZC3HAV1L, MAVS | ALDH1A1 1976/4885CYP1A2 190/4885CYP3A4 57/4885 |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | HCCS, EIF2AK2, MAVS | ALDH1A1 813/4885CYP1A2 350/4885CYP3A4 87/4885 |
| US-20100152456-A1 | Intermediate compound for synthesis of viridiofungin a derivative | ZC3HAV1, ZC3HAV1L, MAVS | ALDH1A1 1976/4885CYP1A2 190/4885CYP3A4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.